FibroBiologics (FBLG) Share-based Compensation (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Share-based Compensation of $3.9 million for Q2 2026, up 430.45% year-over-year from $729000.0 in Q2 2025, and down 6.98% on a QoQ basis from $4.2 million in Q1 2026.
FibroBiologics (FBLG) Share-based Compensation (2023 - 2026) Analysis & Trends
FibroBiologics has reported Share-based Compensation for 4 years, with the latest figure at $3.9 million in Q2 2026.
- Share-based Compensation for Q2 2026 came in at $3.9 million, up 430.45% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.9 million (up 61.39% YoY), and the FY2025 annual result was $4.9 million, down 8.04% from the prior year.
- Share-based Compensation retreated to $3.9 million in Q2 2026, from $4.2 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $5.6 million in Q3 2025 and troughed at $432000.0 in Q4 2023.
- A 4-year average of $1.4 million and a median of $561500.0 in 2024 frame the typical range for Share-based Compensation.
- The largest YoY upside for Share-based Compensation was 870.8% in 2025 against a maximum downside of 4.95% in 2025.
- A 4-year view of Share-based Compensation shows it stood at $432000.0 in 2023, then increased by 25.93% to $544000.0 in 2024, then grew by 29.04% to $702000.0 in 2025, then soared by 450.85% to $3.9 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $3.9 million in Q2 2026, $4.2 million in Q1 2026, and $702000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | FibroBiologics | 9.06 Mn | 9.06 Mn | - | 3.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.87 Mn |
| Jun 30, 2026 | 3.87 Mn |
| Mar 31, 2026 | 694,000.00 |
| Mar 31, 2026 | 694,000.00 |
| Sep 30, 2025 | 704,000.00 |
| Sep 30, 2025 | 704,000.00 |
| Jun 30, 2025 | 6.26 Mn |
| Jun 30, 2025 | 6.26 Mn |
| Mar 31, 2025 | 551,000.00 |
| Mar 31, 2025 | 551,000.00 |
| Dec 31, 2024 | 544,000.00 |
| Dec 31, 2024 | 544,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Jun 30, 2024 | 579,000.00 |
| Jun 30, 2024 | 579,000.00 |
| Mar 31, 2024 | 525,000.00 |
| Mar 31, 2024 | 525,000.00 |
| Dec 31, 2023 | 432,000.00 |
| Dec 31, 2023 | 432,000.00 |